US2019322707A1PendingUtilityA1
Mutated Salmonella Enterica
Est. expiryJan 6, 2034(~7.4 yrs left)· nominal 20-yr term from priority
A61K 39/0275A61K 2039/543C07K 14/255A61K 2039/55A61K 2039/522A61K 2039/552A61K 2039/58Y02A50/30
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A novel, mutated Salmonella enterica serovar Typhimurium vaccine is generated and imparts protective immunity in vaccinated animals for a range of S. enterica serovars. The vaccine can be attenuated or inactivated, including bacterial ghosts or membrane fractions thereof. Immunogenic compositions are included in the invention and methods of generating an immune response.
Claims
exact text as granted — not AI-modified1 - 91 . (canceled)
92 . A method of generating an immune response in an animal against a Salmonella enterica serovar comprising administering to said animal an immunologically effective amount of an immunogenic composition comprising a pharmaceutically acceptable carrier or diluent and a membrane fraction of a mutated S. enterica serovar Typhimurium comprising a null mutation in invR, micA, rybB, rfaH, omrA and omrB genes, wherein said immunologically effective amount of said immunogenic composition generates an immune response in said animal.
93 . The method of claim 92 , wherein said immunogenic composition further comprises an adjuvant.
94 . The method of claim 92 , wherein said mutated S. enterica serovar Typhimurium is selected from the group consisting of S. enterica serovar Typhimurium strain BBS 866 deposited under the accession number NRRL B-50989, S. enterica serovar Typhimurium strain BBS 1134 deposited under the accession number NRRL B-50990, and a combination thereof.
95 . The method of claim 92 , wherein immune response in said animal is cross-reactive with S. enterica serovar Typhimurium, S. enterica serovar Choleraesuis, S. enterica serovar Heidelberg, S. enterica serovar Paratyphi, S. enterica serovar Dublin, S. enterica serovar Abortus-equi, S. enterica serovar Abortus-ovi, S. enterica serovar Enteritidis, S. enterica serovar Arizonae, and S. enterica serovar Gallinarum.
96 .- 98 . (canceled)
99 . The method of claim 92 , wherein said immune response is a humoral immune response.
100 . The method of claim 92 , wherein said immune response is a cellular immune response.Join the waitlist — get patent alerts
Track US2019322707A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.